Monday, November 16, according to early data, the Moderna vaccine is 94.5% effective against coronavirus; making it the second vaccine to have a stunning high success.
The company said its vaccine appears to be 94.5% effective, according to preliminary data from Moderna’s ongoing study. A week ago, competitor Pfizer Inc. announced its own vaccine appeared similarly effective — news that puts both companies on track to seek permission within weeks for emergency use in the U.S.
“These are obviously very exciting results. It’s just as good as it gets — 94.5% is truly outstanding,” said Dr. Anthony Fauci, the Nation’s Top Infectious Disease Doctor.
Dr. Stephen Hoge, Moderna’s President, welcomed the “really important milestone” but said having similar results from two different companies is what’s most reassuring.
“That should give us all hope that actually a vaccine is going to be able to stop this pandemic and hopefully get us back to our lives,” Hoge said. He added: “It won’t be Moderna alone that solves this problem. It’s going to require many vaccines” to meet the global demand.
If the Food and Drug Administration allows emergency use of Moderna’s or Pfizer’s candidate, there will be limited, rationed supplies before the end of the year.